# Ted Fjällman

> Ted Fjällman is a Series A investor at Flerie Invest (London) backing Health Care and Therapeutics. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Flerie Invest](https://shizune.co/investors/profile/flerie-invest)
- Location: London, United Kingdom
- Total investments: 5
- Last investment: Oct 2023
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/tedfjallman/?originalSubdomain=uk

Ted Fjällman is a Chief Executive Officer at NorthX Biologics. He Attended London Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 40% |
| Therapeutics | 2 | 40% |
| Biotechnology | 2 | 40% |
| Pharmaceutical | 2 | 40% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Funding Round | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 1 | 20% |
| United States | 1 | 20% |
| The Netherlands | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Synerkine Pharma | Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models. | $5.6M | Series A | Oct 12, 2023 |  |
| XNK Therapeutics | XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. Thecompany's platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow's cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden | $12.7M |  | Mar 29, 2022 |  |
| XNK Therapeutics | XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. Thecompany's platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow's cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden | $14.2M | Venture - Series Unknown | Mar 29, 2022 |  |
| Geneos Therapeutics | Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $17M | Series A | Mar 24, 2022 |  |
| Synerkine Pharma | Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models. | $4M | Series A | Dec 16, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Thuja Capital](https://shizune.co/investors/profile/thuja-capital) — VC Fund, 2 deals together
- [Global Bio Fund](https://shizune.co/investors/profile/global-bio-fund) — VC Fund, 1 deal together
- [InnovationQuarter](https://shizune.co/investors/profile/innovation-quarter) — VC Fund, 1 deal together
- [Inovio Pharmaceuticals](https://shizune.co/investors/profile/inovio-pharmaceuticals) — VC Fund, 1 deal together
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 1 deal together
- [Sante Ventures](https://shizune.co/investors/profile/sante-ventures) — VC Fund, 1 deal together

## About Flerie Invest

VC Fund

Flerie Invest is a Europian investment firm that makes investments in the health care sector companies.

2 contacts available at Flerie Invest.

| Name | Title | Profile |
| --- | --- | --- |
| Thomas Eldered | Executive Chairman | https://shizune.co/investors/profile/thomas-eldered |
| Ted Fjällman | Partner | https://shizune.co/investors/profile/ted-fj%C3%A4llman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ted Fjällman invest in?

Ted Fjällman invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Funding Round stage. Most of the 5 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ted Fjällman last invest?

The most recent investment recorded for Ted Fjällman closed in Oct 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co